Citigroup Cuts ArriVent BioPharma (NASDAQ:AVBP) Price Target to $20.00

Posted by Stanley Muller on Oct 7th, 2026

ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) had its target price lowered by equities research analysts at Citigroup from $40.00 to $20.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s price target points to a potential upside of 18.45% from the company’s current price.

AVBP has been the subject of a number of other research reports. BTIG Research reduced their price objective on ArriVent BioPharma from $42.00 to $29.00 and set a “buy” rating for the company in a research report on Wednesday. HC Wainwright upped their price target on shares of ArriVent BioPharma from $44.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, August 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of ArriVent BioPharma in a report on Friday, July 17th. Guggenheim cut their target price on shares of ArriVent BioPharma from $45.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Jefferies Financial Group set a $18.00 target price on shares of ArriVent BioPharma in a report on Tuesday. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $29.67.

Check Out Our Latest Stock Analysis on AVBP

ArriVent BioPharma Stock Performance

Shares of AVBP stock traded up $1.79 during trading hours on Wednesday, reaching $16.89. The company had a trading volume of 2,923,780 shares, compared to its average volume of 638,054. The business has a fifty day moving average price of $29.57 and a 200-day moving average price of $29.43. ArriVent BioPharma has a one year low of $11.36 and a one year high of $35.83. The firm has a market cap of $832.57 million, a PE ratio of -4.68 and a beta of 1.34.

ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.06). Equities research analysts forecast that ArriVent BioPharma will post -4.11 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Tema ETFs LLC bought a new stake in ArriVent BioPharma during the 2nd quarter valued at approximately $1,981,000. Deutsche Bank AG bought a new position in shares of ArriVent BioPharma during the second quarter worth $1,361,000. Dimensional Fund Advisors LP grew its stake in ArriVent BioPharma by 758.2% during the first quarter. Dimensional Fund Advisors LP now owns 126,525 shares of the company’s stock valued at $2,918,000 after acquiring an additional 111,782 shares in the last quarter. E Fund Management Co. Ltd. bought a new stake in ArriVent BioPharma in the 2nd quarter valued at $3,798,000. Finally, Bank of America Corp DE boosted its holdings in shares of ArriVent BioPharma by 41.9% during the 1st quarter. Bank of America Corp DE now owns 80,208 shares of the company’s stock valued at $1,850,000 after purchasing an additional 23,687 shares during the last quarter. Institutional investors own 9.48% of the company’s stock.

ArriVent BioPharma News Roundup

Here are the key news stories impacting ArriVent BioPharma this week:

Neutral Sentiment: Trading in AVBP was temporarily halted pending news before the company released its clinical-trial update, reflecting the expected market sensitivity of the announcement.
Negative Sentiment: ArriVent reported that the Phase 3 FURVENT trial of firmonertinib in previously untreated patients with EGFR exon 20 insertion-mutated non-small cell lung cancer failed to meet its primary endpoint of progression-free survival, as assessed by blinded independent central review. ArriVent FURVENT Phase 3 program update
Negative Sentiment: The trial failure affects ArriVent’s lead asset and significantly weakens the near-term investment case. Analysts and industry coverage characterized the outcome as a late-stage setback, with the company reviewing its future plans for firmonertinib. ArriVent reviews firmonertinib plans
Negative Sentiment: Reports described a roughly 58%–60% collapse in the stock following the failed primary endpoint, while the shares approached a new one-year low. The reaction reflects reduced expectations for firmonertinib’s approval and commercial potential. ArriVent shares plunge on FURVENT failure
Negative Sentiment: Levi & Korsinsky announced a potential investor investigation after the trial failure. The notice highlighted shareholder losses and noted that ArriVent had launched a $250 million at-the-market stock offering approximately five months earlier, adding potential litigation and dilution concerns. ArriVent investor investigation notice

ArriVent BioPharma Company Profile

(Get Free Report)

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations.